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Abstract
Background: Reproductive technologies have been extensively debated in the literature. As well,
feminist economists, environmentalists, and agriculturalists have generated substantial debate and
literature on gender. However, the implications for women of health biotechnologies have received
relatively less attention. Surprisingly, while gender based frameworks have been proposed in the
context of public health policy, practice, health research, and epidemiological research, we could
identify no systematic framework for gender analysis of health biotechnology in the developing
world.
Discussion:  We propose sex and gender considerations at five critical stages of health
biotechnology research and development: priority setting; technology design; clinical trials;
commercialization, and health services delivery.
Summary: Applying a systematic sex and gender framework to five key process stages of health
biotechnology research and development could be a first step towards unlocking the opportunities
of this promising science for women in the developing world.
Background
Imagine you are a scientist, a research funder, or a policy-
maker concerned with biotechnology and the developing
world. You know that biotechnology holds the promise of
spawning health and agricultural interventions such as
new vaccines that don't require refrigeration, micronutri-
ent enriched genetically modified plants, and point of
care diagnostics. In addition, you believe that biotechnol-
ogy has the potential to improve global health equity.
Indeed, technology can play an important role, comple-
mentary to social and political interventions, in trans-
forming the lives of millions of people in developing
countries, particularly the poor and rural. At the same
time, however, you are concerned with the impacts of
these new technologies on the health and social well-
being of women, who not only often experience a greater
burden of disease, but also have the responsibility of car-
ing for their families and income-generating obligations
too. How would you think about this topic, and what
questions would you ask, bearing in mind that gender
equity is crucial for human development, economic
growth, and population health?
Feminist economists, environmentalists, and agricultural-
ists have generated substantial debate and literature on
gender equity. For example, gender-based frameworks
have been proposed in the context of public health policy,
practice, health research [1,2], and epidemiological
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research [3]. Gender-based frameworks have also been
developed as tools to integrate gender concerns at all
stages of initiatives [4]. However, we could identify no sys-
tematic framework for gender analysis of health biotech-
nology in the developing world. In this work we propose
key sex and gender factors for considerations at five critical
stages of health biotechnology research and development:
priority setting; technology design; clinical trials; com-
mercialization, and health services delivery.
While our focus is on health biotechnology, this field is
only in its nascent stages in the developing world. There-
fore, we develop the framework based on examples of
health technologies generally, including biotechnology.
By health technology we mean drugs, vaccines, diagnos-
tics, devices, and also nutritional products. While our
examples focus primarily on health, we include nutrition
in our notion of health and also cite examples from agri-
culture by way of analogy, where applicable. We intend
our framework as a simple "points to consider" that can
be used by researchers, funders, and others "in the field."
That is, our audience is users, not primarily researchers in
the field of gender who would need more detailed and
sophisticated frameworks. Before turning to our proposed
framework, it is important to unpack the notions of "sex"
and "gender."
Sex and gender
Understanding the distinction between 'sex' (which is a
biological concept) and 'gender' (which is a social and
behavioral construct) is key to a contextual understanding
of women's health in a world largely dominated by male
norms and biases. Gender relates to how we are perceived
and expected to think and act as men and women because
of the way society is organized, not because of our biolog-
ical differences [5]. For example, a woman's child-bearing
potential relates to biology while child-rearing practices
relate to socially-constructed norms, customs, and values.
Gender-based norms vary across cultures and societies
indicating that women and men are not homogeneous
groups. Gender-based norms in almost all cultures are
unfavorable to women, situating them in disadvanta-
geous positions in relation to men.
Advances in science are enabling an increasing apprecia-
tion of the complexity of human health and of the inter-
actions between biological sex and social gender. Such an
appreciation is helping to uncover factors underpinning
disproportionate disease burdens on women [6,7]
although such discourse is still evolving [8,9]. Further-
more, ongoing research is contributing to the understand-
ing of differential disease burdens between women and
men in regard to health conditions common to both
sexes, in addition to the application of sex and gender
lenses to female-specific diseases alone. For example, in
low and middle income countries females suffer higher
disease burdens of preventable communicable diseases
[10]. This is an important point: sex and gender exert their
influence well beyond 'female-specific' diseases and issues
such as reproduction. In general, sex and gender have a
much wider influence on disease than is usually acknowl-
edged. They influence the etiology, diagnosis, progres-
sion, prevention, treatment, and health outcomes of
disease as well as health-seeking behaviors and exposure
to risk. Whereas sex plays a bigger role in the etiology,
onset, and progression of disease, gender influences dif-
ferential risks, symptom recognition, severity of disease,
access to and quality of care, and compliance with care
[11].
Having briefly considered the notions of sex and gender,
it is now possible to explore five sex and gender consider-
ations in the field of biotechnology.
Discussion
Priority setting and resource allocation: prioritize and 
understand health needs of women
As noted earlier, growing empirical evidence from the health
sciences shows that health conditions can have a biological
basis, be gender-based, or manifest as a result of interactions
between the two. In poor countries, given their vulnerable
and disempowered status, women are disproportionately
affected by poverty, lack of access to care, and diseases, in
addition to sex-specific differentials in health conditions.
From an ethics perspective, such evidence compels action.
For example, the theory of utilitarianism (perform good for
the greatest number of people), the principle of solidarity
[12] (cooperation with the goal of mutually beneficial out-
comes amongst a world community of interdependent
states), and global justice cosmopolitism [13] (suffering cre-
ates a moral demand that those who are able to help should
do so, regardless of locality) all demand that health gender
inequities should inform resource allocation on the part of
health research sponsors. In the malaria context, for exam-
ple, above having funded research that showed that pregnant
women are more vulnerable to malaria, sponsors of health
research should prioritize funding to enhance our under-
standing of how gender, poverty, and reproductive biology
influence vulnerability to, and the experience of, malaria,
and how these factors influence health-seeking behavior
[14] in developing world settings. For instance, studies have
shown that women's access to resources and their bargaining
power within the household have a significant influence on
their treatment-seeking behavior for children with malaria
(See Malaria Knowledge Program Policy Brief on Gender
Perspectives in Malaria Management at http://www.health
link.org.uk). A policy research report from Gender and
Development examining gender and preferences for malaria
prevention in Tigray, Ethiopia illuminates how married
women are also willing to pay more to prevent malaria in
their household than married men (See the paper by Lampi-
etti et al at http://siteresources.worldbank.org/INTGENDER/BMC International Health and Human Rights 2009, 9:15 http://www.biomedcentral.com/1472-698X/9/15
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Resourcewp3.pdf). Further research is needed to explore
how women's responsibility for children's healthcare and
healthcare payments threaten strategic interests related to
women's social and economic independence, as well as how
different health financing strategies of men and women
impact on individual and household livelihoods (See
Malaria Knowledge Program Policy Brief on Gender Perspec-
tives in Malaria Management at http://www.health-
link.org.uk).
Technology design: devise gender-responsive technology
The United Nations Food and Agriculture Organization
(FAO) notes that: "structural changes in rural economies,
combined with the emergence of new technologies, are
likely to intensify female marginalization even further in
the future unless government officials and community
leaders systematically consider and address rural women's
needs, and identify and deliver gender-responsive technol-
ogy driven by gender specific technology demands." [15]
While the importance of gender-responsive biotechnology
has been recognized in the field of agriculture, it is arguably
not as recognized in the field of health biotechnology.
Given the historical gender disparities in sponsorship of
health research, aside from prioritizing the sponsorship of
research that addresses the health concerns of women, spon-
sors should, in addition, actively encourage the development
of gender-sensitive health biotechnology. For example,
female condoms and vaginally administered microbicide
products allow women to control their reproductive health
in instances where they are powerless to negotiate condom
use with their male partners. On the other hand, the gender
implications of certain HIV vaccines technologies must be
given careful thought. For instance, there are several ways to
administer a vaccine to induce mucosal immune response to
HIV. Research has shown that the strongest immune
response occurs at the site of vaccination [16]. Thus, given
that heterosexual vaginal sex is the primary route of HIV
infection in much of the developing world, funding priority
should be afforded to vaginally administered HIV vaccines
[17]. However, a vaginally administered HIV vaccine may
encounter greater resistance in some settings on cultural and
social grounds compared to a vaccine that could be swal-
lowed or injected. If such a factor is discounted, it could
result in low uptake of the technology. Accordingly, mean-
ingful gender-sensitive efforts must be made to prospectively
engage men and women about the technology prior to its
commercialization.
Clinical trials: enroll women, and collect, analyze, and 
report sex-specific data
The inclusion of women as research participants in trials
of biotechnology products is fundamental to generate
generalisable knowledge. Historically, in the United States
– the world's largest sponsor of health research – women
have been underrepresented in clinical drug trials such
that data may not generalize beyond the male population
[18]. Although US federal policy was amended in 1993,
gradually changing this state of affairs [19], this policy
applies only to federally-sponsored research [20]; indus-
try sponsors 80% of clinical trials in US (See EDICT
Project Letter at http://www.bcm.edu/edict/PDF/
CMS_EDICT_Response_to_20070719_Reconsideration.p
df). Such a bias persists elsewhere too. For example,
despite clear evidence of HIV/AIDS disproportionately
affecting women in the developing world by the end of
the twentieth century, in 2002 women were still report-
edly underrepresented in HIV/AIDS clinical trials in some
developing countries [21]. In order to develop biotech-
nologies that can have a meaningful effect on gender
equity, sponsors and investigators should ensure that the
male-female spread in a trial matches the targeted patient
population and that the trial is sufficiently powered to test
sex and gender based differences, regardless of whether
regulatory authorities require so. Doing so will require rel-
evant community engagement with men and women, and
being sensitive to local gender norms and beliefs.
In some settings patriarchal socio-cultural norms, tradi-
tions, and practices may hinder the representation of
women in research (for instance, where male family mem-
bers or village elders prohibit women from autonomously
participating in research). In such instances, patriarchal
gatekeepers should be meaningfully engaged by investiga-
tors, and where necessary, by authorities, and motivated
to allow for the participation of the women in research.
Investigators should resist treating women as a homoge-
nous group. This could result in the needless over-repre-
sentation of particularly vulnerable cohorts of women
in certain trials, such as sex workers (See ARVAC bulletin
at http://www.arvac.org.uk/docs/info_bull100c.html),
whose research findings, in addition, may not be general-
isable to other women.
A fundamental challenge is accounting for the biological
differences between men and women during a study. This
may seem elementary given clear evidence of pharmacok-
inetic differences between men and women and regula-
tory requirements in some countries for sex-specific
analyses to be done. However, research still often fails to
collect, analyze, and report data specific to men and
women (See Medscape article at http://doctor.med
scape.com/viewarticle/517016) and to account for the
biological differences between both sexes in relation to
the intervention being studied. For instance, studies have
shown alterations in drug metabolism in relation to
phases of menstrual cycle, during pregnancy, or after men-
opause [22]. These differences are likely to affect not only
the pharmaco-kinetics of small molecules but also biolog-
icals. To date, though, very few studies on the relationship
between menses and ARVs have been performed [23].
This despite higher CD4 counts having been found to beBMC International Health and Human Rights 2009, 9:15 http://www.biomedcentral.com/1472-698X/9/15
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associated with lower incidence of menstrual problems
among HIV-positive women [24,25] and lower rates of
ARV adherence having been reported during menstrual
weeks compared with premenstrual weeks [26]. As HIV-
infected women in the developing world live longer
because of increased access to ARVs, the relationship
between menopause and ARVs will also have to receive
more attention [27]. Focusing on such sex-specific factors
and understanding their gender implications have impor-
tant implications for development given that a detrimen-
tal impact on the health and productivity women will
affect both their role of primary caregivers in society and
as important drivers of formal and informal economies.
Commercialization: marketing that takes into 
consideration women consumers
It has been argued that "the introduction of agricultural bio-
technology guided solely by markets, without consideration
of other, non-market conditions is ...likely to exacerbate
rather than ameliorate racial, class and gender divisions"
(See article by Noah Zerbe, York University at http://
www.yorku.ca/cerlac/temuco/articulos/Zerbe2.doc).
Despite the central role of women in food production and
food security, gender bias has been recorded in the provision
of agricultural extension services, access to credit, agro-tech-
nological innovations, technology transfer, and land rights
[28,29]. Given the gender bias in technology transfer, as
higher-yielding agricultural biotechnology crop varieties are
commercialized, the risk exists that men may displace house-
hold gardens traditionally maintained by women. This
could threaten food security and women's livelihoods. Thus,
commercializing a new technology should be seen as more
than simply placing the product on shelves where it can be
accessed by women consumers. Aside from devising a frame-
work to manage the identification and delivery of technol-
ogy support services by government and other providers
based on needs articulated by women, the FAO recommends
capacity building, research and development, enhanced col-
laboration, strengthened technology transfer centres and
policy change, to support the creation for, and adoption by,
women, of relevant technologies [17]. In the context of
malaria in Africa, for example, successful commercialization
strategies have included relevant public engagement and
introducing a voucher system administered through antena-
tal clinics which allowed pregnant women to buy treated
anti-malaria nets at a reduced price (See Medicus Mundi bul-
letin at http://www.medicusmundi.ch/mms/services/bulle
tin/bulletin200003/kap006lengeler.html). This encouraged
pregnant women to protect themselves and their new-borns
from malarial infection.
Health services delivery: Enhancing women's access to 
affordable services
Optimal health service delivery for women is not truly
possible unless the long-term systemic issues that impact
on the status of women are given adequate attention. For
instance, given high levels of gender-based violence in
many settings, meaningful efforts must be made to ensure
that post-exposure anti-HIV interventions are accessible to
sexual assault survivors everywhere, regardless of their
geographic or socio-economic status. Similarly, biotech-
nology-based point-of-care diagnostics, which allow diag-
nostic services to be brought to women's doorsteps,
should be made widely available as it facilitates access to
health care, as and when needed. In sub-Saharan Africa,
long distances to access health care typically deter women
from seeking screening and care. Here, rapid point-of
care-diagnostics would allow for the rapid screening and
detection of, for example, Neisseria gonorrhoeae (Ng)
and Chlamydia trachomatis (Ct) infections, both of
which are often asymptomatic. This could result in 40–
60% more Ng/Ct and HIV infections being averted and
substantial costs savings for governments [30].
However, hoping that women understand and will want
to embrace a technology is not a guarantee that they will
actually have the opportunity to do so. Empirical evidence
indicates that although women in some countries access
more health services than men [31], women's overall
underutilization of health services is well documented in
many developing countries. For instance, even though
women in India report more illness than men, hospital
records show that men receive more treatment; in Thai-
land, men are six times more likely than women to seek
clinical treatment for malaria, a disease that affects
women and men similarly; and in Brazil, the Dominican
Republic, Jamaica, Paraguay, and Peru, low-income
women underuse health services [11]. In order to redress
such disparities in the access, outcomes, and quality of
health care, concerted effort is needed to understand and
establish mechanisms to ensure that women receive equi-
table access to biotechnological innovations.
Summary
Science, ethics, commercialization, and politics all influ-
ence the adoption of health biotechnology in the develop-
ing world [32]. In turn, gender can influence all these
forces. Applying a systematic gender framework to five key
process stages – priority setting, product development,
clinical trials, commercialization, and delivery – could be
a first step towards unlocking the opportunities of this
promising science for women in the developing world.
Biotechnology Gender Framework: summary
1. Prioritize funding for science that addresses the health
needs of women.
2. Devise gender-responsive technology.
3. Ensure gender equity in clinical trial design.BMC International Health and Human Rights 2009, 9:15 http://www.biomedcentral.com/1472-698X/9/15
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4. Employ a range of commercialization strategies appro-
priate for women.
5. Enhance access to health care and service delivery for
women.
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